Early benefit of mepolizumab on small airways in severe asthma: insights from the IMPOSE study.

ABSTRACT:

Background

Severe eosinophilic asthma adversely affects small airway function, but effective therapeutic options are limited. The IMPOSE trial (www.clinicaltrials.gov identifier number NCT05147155) assessed the early and sustained effects of mepolizumab on small airways in patients with severe eosinophilic asthma using impulse oscillometry (IOS).

Methods

The study comprised 130 participants: 40 with uncontrolled severe asthma initiating mepolizumab, 40 with well-controlled severe asthma and 50 healthy controls. Lung function was assessed with IOS, spirometry and plethysmography at baseline and at 1, 3 and 6 months post-treatment. Clinical outcomes included asthma control, quality of life and medication adherence.

Results

Small airway function significantly improved wi

SUBMITTER: Kotsiou OS 

PROVIDER: S-EPMC12183737 | biostudies-literature | 2025 May

REPOSITORIES: biostudies-literature